People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their odds for a dangerous blood clot, new research finds.

New findings presented at ASH indicated that GLP-1 agonists led to a significant reduction in the risk for dangerous blood clots, regardless of patients’ obesity status.

TUESDAY, Dec. 10, 2024 (HealthDay News) -- People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their odds for a dangerous blood clot, new research finds.

Propensity-score matched analysis showed that VTE rates at 1 year were 20% lower for patients starting on a GLP-1 drug rather than a DPP-4 inhibitor (6.5 vs 7.9 per 1,000 patient-years, HR 0.80, 95% CI 0.75-0.85, P <0.001), reported Rushad Patell, MD, of Harvard Medical School in Boston.